» Articles » PMID: 21146684

Comparison of the Racial/ethnic Prevalence of Regular Aspirin Use for the Primary Prevention of Coronary Heart Disease from the Multi-ethnic Study of Atherosclerosis

Overview
Journal Am J Cardiol
Date 2010 Dec 15
PMID 21146684
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

In 2002, the United States Preventive Services Task Force and the American Heart Association recommended aspirin for the primary prevention of coronary heart disease in patients with Framingham risk scores ≥ 6% and ≥ 10%, respectively. The regular use of aspirin (≥ 3 days/week) was examined in a cohort of 6,452 White, Black, Hispanic, and Chinese patients without cardiovascular disease in 2000 to 2002 and 5,181 patients from the same cohort in 2005 to 2007. Framingham risk scores were stratified into low (<6%), increased (6% to 9.9%), and high (≥ 10%) risk. In 2000 to 2002 prevalences of aspirin use were 18% and 27% for those at increased and high risk, respectively. Whites (25%) used aspirin more than Blacks (14%), Hispanics (12%), or Chinese (14%) in the increased-risk group (p <0.001). Corresponding prevalences for the high-risk group were 38%, 25%, 17%, and 21%, respectively (p <0.001). In 2005 to 2007 prevalences of aspirin use were 31% and 44% for those at increased and high risk, respectively. Whites (41%) used aspirin more than Blacks (27%), Hispanics (24%), or Chinese (15%) in the increased-risk group (p <0.001). Corresponding prevalences for the high-risk group were 53%, 43%, 38%, and 28%, respectively (p <0.001). Racial/ethnic differences persisted after adjustment for age, gender, diabetes, income, and education. In conclusion, regular aspirin use in adults at increased and high risk for coronary heart disease remains suboptimal. Important racial/ethnic disparities exist for unclear reasons.

Citing Articles

Impact of aspirin on pancreatic cancer in the elderly: analysis of socioeconomic status and outcomes of national matched cohorts.

Suenghataiphorn T, Lohawatcharagul T, Kulthamrongsri N, Danpanichkul P, Suparan K, Polpichai N Ann Gastroenterol. 2024; 37(6):750-757.

PMID: 39568713 PMC: 11574160. DOI: 10.20524/aog.2024.09179.


Structural and social determinants of health: The multi-ethnic study of atherosclerosis.

Besser L, Forrester S, Arabadjian M, Bancks M, Culkin M, Hayden K PLoS One. 2024; 19(11):e0313625.

PMID: 39556532 PMC: 11573213. DOI: 10.1371/journal.pone.0313625.


US population qualifying for aspirin use for primary prevention of cardiovascular disease.

Huang A, Navar A, Ayers C, Rohatgi A, Michos E, Virani S Am J Prev Cardiol. 2024; 18:100669.

PMID: 38681065 PMC: 11046250. DOI: 10.1016/j.ajpc.2024.100669.


Colorectal Cancer Survivors' Receptivity toward Genomic Testing and Targeted Use of Non-Steroidal Anti-Inflammatory Drugs to Prevent Cancer Recurrence.

OMalley D, Blair C, Greenbaum A, Wiggins C, Rajput A, Chiu V J Community Genet. 2022; 13(2):201-214.

PMID: 34997901 PMC: 8941057. DOI: 10.1007/s12687-021-00574-9.


Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease.

Chen Y, Yin C, Li Q, Yu L, Zhu L, Hu D Front Cardiovasc Med. 2021; 8:720113.

PMID: 34540919 PMC: 8446611. DOI: 10.3389/fcvm.2021.720113.


References
1.
Greving J, Buskens E, Koffijberg H, Algra A . Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008; 117(22):2875-83. DOI: 10.1161/CIRCULATIONAHA.107.735340. View

2.
Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-62. DOI: 10.1016/s0140-6736(98)04311-6. View

3.
de Gaetano G . Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001; 357(9250):89-95. DOI: 10.1016/s0140-6736(00)03539-x. View

4.
. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice.... Lancet. 1998; 351(9098):233-41. View

5.
Pearson T, Blair S, Daniels S, Eckel R, Fair J, Fortmann S . AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association.... Circulation. 2002; 106(3):388-91. DOI: 10.1161/01.cir.0000020190.45892.75. View